Faisal Zain stands at the forefront of a technological revolution, bringing years of expertise in the manufacturing and implementation of high-stakes medical devices used for diagnostics and treatment. As an authority on health technology, he has navigated the complexities of integrating advanced software into clinical workflows, ensuring that innovation never compromises patient safety. His deep understanding of how devices interact with the human element makes him a vital voice as the industry shifts from simple automated tools to sophisticated, generative systems that mimic human decision-making.
The following discussion explores the monumental shift in how regulatory bodies view artificial intelligence, moving away from a traditional binary software model toward a competency-based evaluation similar to the licensing of a physician. We delve into the challenges of an unbounded evaluation space where inputs and outputs are limitless, the critical feedback from over 300 industry stakeholders, and the practicalities of maintaining accountability in a probabilistic digital environment.
How do you view the departure from the traditional regulatory framework that has governed medical software for the last twenty years?
For two decades, we have operated under a relatively predictable paradigm where software functioned much like a digital calculator. You had a specific input—let’s say a chest X-ray—and the software would provide a binary signal, such as a “yes” or “no” for a condition like a pneumothorax. This “X in, Y out” model was straightforward from an evidentiary standpoint because the boundaries of the software’s behavior were clearly defined and easily tested. However, we are now entering a landscape where generative AI tools provide unbounded outputs, which fundamentally breaks that 20-year-old mold. We are moving from a world of fixed signals to a world of limitless text and reasoning, which requires a complete overhaul of our safety and efficacy proofs.
The idea of assessing a piece of code based on clinical judgment rather than a fixed dataset is radical; how does this mirror the way we certify human doctors?
This is perhaps the most profound conceptual shift in medical device history, as we are starting to treat generative AI more like a colleague than a piece of hardware like a heart valve or a defibrillator. When a radiologist is trained, they are evaluated on their clinical judgment, their ability to communicate findings, and their adherence to safety boundaries over a long period. No physician has ever been tested against every single possible chest X-ray they might encounter in a 30-year career because that simply isn’t practical or possible. By applying this same logic to AI, we are acknowledging that these models possess a probabilistic nature that requires a “competency” assessment rather than a one-time performance test against a static spreadsheet.
With the FDA receiving more than 300 distinct comments on its recent discussion paper, what are the critical tensions between industry innovation and regulatory accountability?
The volume of feedback—more than 300 individual submissions—highlights a massive anxiety within the industry regarding where the buck stops when a generative tool makes a mistake. There is a very real concern that the probabilistic nature of these outputs might diffuse accountability across a messy ecosystem of developers, clinicians, and hospital institutions. As medical technology leaders, we must ensure that the “impossibility” of testing every scenario does not become an excuse for a lack of transparency or safety. We are essentially trying to build a framework that balances the “agentic” capabilities of these tools with the rigid safety standards we expect from any other life-saving medical instrument.
As we move away from academic papers toward enforceable policy, what should developers expect in terms of the timeline and the influence of the current administration?
It is essential to recognize that this is no longer just a thought exercise or a series of academic inquiries; the drive for formal policy is coming from the highest levels, including the HHS Secretary and the White House. This administration has made the development of a robust AI policy a top priority, ensuring that we aren’t just reacting to technology but actively shaping its clinical integration. While the timeline is naturally cautious to allow for a thoughtful synthesis of those 300-plus comments, we are looking at a horizon of months rather than years. Starting from 2026, we should expect to see draft guidance that will finally provide the industry with a clear roadmap for bringing these “physician-like” tools to the bedside safely.
What is your forecast for the integration of generative AI within the clinical ecosystem over the coming years?
I anticipate a future where the line between a medical device and a medical professional continues to blur, leading to a hybrid model of care where AI is “credentialed” much like a human staff member. From 2026 to 2028, I expect we will see a surge in agentic AI tools that don’t just flag issues but actively participate in the diagnostic dialogue, requiring us to refine our oversight to be as dynamic as the software itself. We will move away from static software updates to a system of continuous monitoring of an AI’s “clinical judgment” to ensure it hasn’t drifted from its safety boundaries. Ultimately, this will lead to a more personalized and responsive healthcare system, but only if we maintain the rigorous, human-centered accountability that the FDA is currently drafting.
